By Patrick Wingrove and Dan LevineDec 17 (Reuters) - The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental... Read more
Usnews - Dec 17
Pliant Therapeutics, Inc. (NASDAQ:PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.PLRX stock is showing notable weakness. Check out the latest moves here.Pliant Therapeutics on Thursday released interim data from its Phase 1 dose esc... Read more
Benzinga - Dec 04
ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately... Read more
The Joplin Globe - Nov 14
Merck’s Cidara Therapeutics acquisition brings a lead program with potential to become a first-in-class drug for preventing influenza infection. A Phase 3 study is already underway, timed to coincide with the start of the flu season in the Northern Hemisphere. The post Merck Makes Big Antiviral M... Read more
Medcity News - Nov 14
Coherent Market Insights has released a report titled "Placebo Drug Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", which includes market percentage records and a thorough enterprise analysis. This report looks at the market's competition, geographic distributi... Read more
Openpr.com - Nov 13
Coherent Market Insights has released a report titled "Smart Capsule Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", which includes market percentage records and a thorough enterprise analysis. This report looks at the market's competition, geographic distribut... Read more
Openpr.com - Nov 12
Merck's enlicitide pill lowered LDL cholesterol by up to 60%, matching injectables like Repatha and offering an easier option for patients. Read more
Stat - Nov 08
The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk. Read more
The New York Times - Nov 08
Achmea Investment Management B.V. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 3.9% during the second quarter, Holdings Channel.com reports. The firm owned 175,593 shares of the company’s stock after selling 7,220 shares during the period. Achmea Investment Mana... Read more
Americanbankingnews - Nov 07
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.Veterinary Biologics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?The market size for veterinary Read more
Openpr.com - Nov 06
